No profile data available.
Daré Bioscience, Inc. (DARE) is a healthcare company in the additional infection treatment pharmaceuticals industry, based in San Diego, United States, with about 21 full-time employees.
It reported revenue of $9,784 for fiscal year 2024, down 99.7% from fiscal year 2023, and net income of -$4.05 million. In Q3 2025 (the quarter ended September 30, 2025) revenue was $2,262, down 94.6% from a year before. Its market capitalization was $15.21 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2024; market data as of October 9, 2026.
Daré Bioscience, Inc. develops therapies in the areas of contraception, pelvic pain, fertility, infectious disease, menopause, and sexual and vaginal health in the United States. The company offers XACIATO, a lincosamide antibacterial gel for the treatment of bacterial vaginosis.
Daré Bioscience reported $9,784 in revenue for fiscal year 2024, down 99.7% from $2.81 million in fiscal year 2023. In Q3 2025 revenue was $2,262.
$15.21 million as of October 9, 2026.
Listed companies of a similar size in the same industry (additional infection treatment pharmaceuticals) include Tarsus Pharmaceuticals, Inc. (TARS), Scynexis, Inc. (SCYX), Pulmatrix, Inc. (PULM), 60 Degrees Pharmaceuticals, Inc. (SXTP).